Pancreatic cancer ‘mismatch’ in Lynch syndrome

OBJECTIVE: Immune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable/metastatic solid tumours exhibiting mismatch repair (MMR) deficiency. Lynch syndrome (LS), caused by autosomal dominant germline mutations of a MMR gene, predisposes to the development of MMR-defic...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Open Gastroenterol
Auteurs principaux: Hendifar, Andrew E, Larson, Brent K, Rojansky, Rebecca, Guan, Michelle, Gong, Jun, Placencio, Veronica, Tuli, Richard, Hitchins, Megan
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2019
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6577306/
https://ncbi.nlm.nih.gov/pubmed/31275582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2019-000274
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires